Synchron Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 125

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 52

Synchron General Information

Description

Developer of an implantable stent-rode designed to create a brain-computer interface. The company offers a minimally invasive implantable device embedded with electrode arrays that interpret signals from the brain to modulate neural activity in specific regions, enabling patients with motor impairments to regain some level of control over digital devices, prosthetics, or other assistive technologies using their thoughts.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Navy Yard
  • Brooklyn
  • New York, NY 11205
  • United States
Primary Industry
Therapeutic Devices
Other Industries
Other Devices and Supplies
Decision/Risk Analysis
Corporate Office
  • Navy Yard
  • Brooklyn
  • New York, NY 11205
  • United States

Synchron Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Synchron Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Secondary Transaction - Private 01-Nov-2026 Completed Clinical Trials - General
8. Later Stage VC (Series D) 01-Aug-2025 Completed Clinical Trials - General
7. Later Stage VC (Series C) 02-Dec-2022 Completed Clinical Trials - General
6. Angel (individual) 07-Feb-2022 Completed Clinical Trials - General
5. Grant 26-Aug-2021 Completed Clinical Trials - General
4. Later Stage VC (Series B) 03-Jun-2021 Completed Clinical Trials - General
3. Grant 24-Jul-2020 Completed Clinical Trials - General
2. Early Stage VC (Series A) 01-Mar-2018 $10M $25M Completed Product Development
1. Seed Round $15M $15M Completed Product Development
To view Synchron’s complete valuation and funding history, request access »

Synchron Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D
Series C-1
Series C
Series B-1
Series B 2,849,155 $0.000100 8% $12.64 $12.64 1x $12.64 12.75%
Series A 1,770,224 $0.000100 8% $2 $2 1x $2 7.92%
To view Synchron’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Synchron Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an implantable stent-rode designed to create a brain-computer interface. The company offers a minimally inv
Therapeutic Devices
New York, NY
125 As of 2026

New York, NY
 

Fremont, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Synchron Competitors (9)

One of Synchron’s 9 competitors is Precision Neuroscience, a Venture Capital-Backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Precision Neuroscience Venture Capital-Backed New York, NY
Neuralink Venture Capital-Backed Fremont, CA
Blackrock Neurotech Venture Capital-Backed Salt Lake City, UT
Neurable Venture Capital-Backed Boston, MA
Paradromics Venture Capital-Backed Austin, TX
You’re viewing 5 of 9 competitors. Get the full list »

Synchron Patents

Synchron Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260339437-A1 Use of secondary data during neural decoding in brain computer interface systems Pending 25-Apr-2025
WO-2026224673-A1 Use of secondary data during neural decoding in brain computer interface systems Pending 25-Apr-2025
WO-2026207178-A1 Adaptive user interfaces for brain computer interface systems Pending 26-Mar-2025
US-20260277327-A1 Context-aware neural signal decoding Pending 16-Mar-2025
WO-2026198344-A1 Context-aware neural signal decoding Pending 16-Mar-2025 G06F3/015
To view Synchron’s complete patent history, request access »

Synchron Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Synchron Investors (52)

Investor Name Investor Type Holding Investor Since Participating Rounds
3cap Venture Capital Minority
Armyn Capital Venture Capital Minority
Axial Partners (United States) Venture Capital Minority
Destiny Venture Capital Minority
Double Point Ventures Venture Capital Minority
You’re viewing 5 of 52 investors. Get the full list »

Synchron Investments & Acquisitions (3)

Synchron’s most recent deal was a Corporate with Acquandas. The deal was made on 01-Feb-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Acquandas 01-Feb-2024 Corporate Other Commercial Products
Rare Element Resources 02-Oct-2017 PIPE Gold Mining
SmartStent 04-May-2016 Merger/Acquisition Diagnostic Equipment
To view Synchron’s complete investments and acquisitions history, request access »

Synchron FAQs

  • When was Synchron founded?

    Synchron was founded in 2016.

  • Where is Synchron headquartered?

    Synchron is headquartered in New York, NY.

  • What is the size of Synchron?

    Synchron has 125 total employees.

  • What industry is Synchron in?

    Synchron’s primary industry is Therapeutic Devices.

  • Is Synchron a private or public company?

    Synchron is a Private company.

  • What is Synchron’s current revenue?

    The current revenue for Synchron is .

  • How much funding has Synchron raised over time?

    Synchron has raised $340M.

  • Who are Synchron’s investors?

    3cap, Armyn Capital, Axial Partners (United States), Destiny, and Double Point Ventures are 5 of 52 investors who have invested in Synchron.

  • Who are Synchron’s competitors?

    Precision Neuroscience, Neuralink, Blackrock Neurotech, Neurable, and Paradromics are some of the 9 competitors of Synchron.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process